###begin article-title 0
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
Differential Methylation Pattern of ID4, SFRP1, and SHP1 between Acute Myeloid Leukemia and Chronic Myeloid Leukemia
###end article-title 0
###begin p 1
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DAB2IP</italic>
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DLC-1</italic>
###xml 210 220 210 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H-cadherin</italic>
###xml 222 225 222 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 227 242 227 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Integrin &#945;4</italic>
###xml 244 249 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 251 256 247 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 262 266 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 503 506 499 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 508 513 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 519 523 515 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 683 688 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DLC-1</italic>
###xml 690 696 686 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DAB2IP</italic>
###xml 698 708 694 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H-cadherin</italic>
###xml 710 725 706 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Integrin &#945;4</italic>
###xml 731 736 723 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
###xml 577 585 <span type="species:ncbi:9606">patients</span>
To gain insight into the differential mechanism of gene promoter hypermethylation in acute and chronic leukemia, we identified the methylation status on one part of 5'CpG rich region of 8 genes, DAB2IP, DLC-1, H-cadherin, ID4, Integrin alpha4, RUNX3, SFRP1, and SHP1 in bone marrows from acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients. Also, we compared the methylation status of genes in AML and CML using methylation-specific PCR (MSP). The frequencies of DNA methylation of ID4, SFRP1, and SHP1 were higher in AML patients compared to those in CML patients. In contrast, no statistical difference between AML and CML was detected for other genes such as DLC-1, DAB2IP, H-cadherin, Integrin alpha4, and RUNX3. Taken together, these results suggest that these methylation-controlled genes may have different roles in AML and CML, and thus, may act as a biological marker of AML.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 457 465 <span type="species:ncbi:9606">patients</span>
Genomic DNA hypomethylation has been observed in the peripheral blood mononuclear cells of leukemia patients and in tumor cells of patients with B-cell lymphoproliferative diseases (1). DNA methylation may affect karyotypic stability, may influence euchromatin-heterochromatin interactions, and has been correlated with disease progression (2). On the other hand, promoters of some tumor suppressive genes are often hypermethylated (3-6). For example, some patients with lymphomas do not express tumor suppressor genes because the promoters of these genes are methylated.
###end p 3
###begin p 4
Leukemia is a hematological cancer of the bone marrow and lymphatic system. In leukemia, bone marrow produces a large number of abnormal white blood cells, which overwhelm the other types of blood cells, including red blood cells and platelets, thus impairing the production of normal white blood cells. In clinical classification, leukemia can be classified as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). AML is a serious and lethal disease that affects adults. CML is a clonal disease of stem cell origin that is characterized by the presence of the Philadelphia chromosome (Ph+), which has been named t(9,22)(q34:q11). Its fusion gene product, Bcr-Abl, is a constitutively active tyrosine kinase. These facts suggest that somewhat different mechanisms may be involved in AML and CML. Nevertheless, the differential factors through which they produce a different type of leukemia are not yet completely understood.
###end p 4
###begin p 5
###xml 75 85 75 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E-cadherin</italic>
###xml 87 97 87 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DAP kinase</italic>
###xml 118 120 118 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ER</italic>
###xml 136 141 136 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INK4B</sup>
###xml 133 141 133 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p15<sup>INK4B</sup></italic>
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 203 209 203 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DAB2IP</italic>
###xml 211 216 211 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DLC-1</italic>
###xml 218 228 218 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H-cadherin</italic>
###xml 230 233 230 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 235 250 235 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Integrin &#945;4</italic>
###xml 252 257 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 259 264 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 270 274 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 384 386 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 387 389 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 366 371 <span type="species:ncbi:9606">human</span>
###xml 564 572 <span type="species:ncbi:9606">patients</span>
In hematopoietic malignancies, hypermethylation of several genes including E-cadherin, DAP kinase, estrogen receptor (ER) alpha, and p15INK4B are associated with gene inactivation (7-10). Genes, such as DAB2IP, DLC-1, H-cadherin, ID4, Integrin alpha4, RUNX3, SFRP1, and SHP1, has been identified as being implicated in aberrant DNA methylation during development of human malignancy (11-18). In order to gain insight into the differential epigenetic alterations in leukemia, we investigated the methylation statuses at selected locus of these genes in AML and CML patients using a methylation-specific polymerase chain reaction (MSP).
###end p 5
###begin title 6
MATERIALS AND METHODS
###end title 6
###begin title 7
Sample collection
###end title 7
###begin p 8
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 411 419 <span type="species:ncbi:9606">patients</span>
###xml 547 555 <span type="species:ncbi:9606">patients</span>
Diagnostic bone marrow samples were obtained from 23 patients with AML and 21 patients with CML. The samples were gathered by the Division of Hematology/Oncology (Department of Internal Medicine, Korea University Medical Center, Seoul, Republic of Korea) and analyzed by pathologist. Institutional review board approval and informed consent were obtained (KUMC-IRB-2006011-P-1, KUMCIRB-2006012-P-2). Of the AML patients, 17 males and 6 females were included, with ages ranging from 26 to 78 yr, at a median age of 45.61 (SD, 15.56) yr. Of the CML patients, 11 males and 10 females were included, with ages ranging from 18 to 75 yr (mean+/-SD, 49.91+/-16.53). As controls, 22 normal peripheral bloods were obtained from healthy volunteers (11 males and 10 females) ranging from 20 to 78 yr of age (mean+/-SD, 45.36+/-20.64).
###end p 8
###begin title 9
Sodium bisulfite treatment and MSP
###end title 9
###begin p 10
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 799 806 787 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 1210 1212 1194 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1119 1124 <span type="species:ncbi:9606">human</span>
Chemical modification was performed as described previously, with minor modifications (19). In brief, 1 microg of genomic DNA was denatured by incubation with 0.2 M NaOH for 10 min at 37℃, followed by the addition of 550 microL of 3 M sodium bisulfite (pH 5.0) (Sigma, St. Louis, MO, U.S.A.) and 10 mM hydroquinone (Sigma), which was brought to a final volume of 600 microL. The mixtures were incubated at 55℃ for 16 hr, and the modified DNA was then desalted with the Wizard Clean-Up system (Promega Corp., Madison, WI, U.S.A.). We performed polymerase chain reaction (PCR) using specific PCR primers capable of distinguishing between methylated and unmethylated DNA sequences. The primers for the unmethylated and methylated DNA sequences, PCR product size, and annealing temperature are shown in Table 1. The MSP primer sets were selected at the 5'-CpG island regions of genes using the MethPrimer software (). The PCR conditions were as follows: initial denaturation and hot start at 95℃ for 5 min, and cycles consisting of 30 sec at 95℃, 30 sec at the annealing temperature, and 30 sec at 72℃. In addition, SCK, a human cholangiocarcinoma cell line, was used as positive control for Integrin alpha4 gene (20).
###end p 10
###begin title 11
Statistical analysis
###end title 11
###begin p 12
###xml 298 299 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
MSP results were analyzed as a dichotomous variable based on the presence or absence of gene methylation. The MSP results of tumor and normal samples were compared and analyzed with the Pearson chi-square test (Version 12; SPSS Inc., Chicago, IL, U.S.A.). Statistical significance was defined as a P value of <0.05.
###end p 12
###begin title 13
RESULTS
###end title 13
###begin p 14
###xml 216 220 216 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 240 243 240 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 272 282 272 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H-cadherin</italic>
###xml 300 305 300 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DLC-1</italic>
###xml 327 333 327 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DAB2IP</italic>
###xml 338 343 338 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 448 452 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 471 481 471 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H-Cadherin</italic>
###xml 500 503 500 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 525 530 525 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 550 556 550 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DAB2IP</italic>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DLC-1</italic>
###xml 565 580 565 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Integrin &#945;4</italic>
###xml 586 591 582 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 593 599 589 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 702 709 698 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
The multiple genes were found to be methylated in bone marrow from patients with AML or CML. Specifically, the frequencies of promoter hypermethylation at selected locus in the 23 AML samples were: 78.3% (18/23) for SHP1, 65.2% (15/23) for ID4 and SFRP1, 26.1% (6/23) for H-cadherin, 8.7% (2/23) for DLC-1, and 4.3% (1/23) for DAB2IP and RUNX3. The frequencies of DNA hypermethylation at selected locus in the 21 CML samples were: 28.6% (6/21) for SHP1, 19.0% (4/21) for H-Cadherin, 14.3% (3/21) for ID4, 9.5% for (2/21) for SFRP1, and 0% (0/21) for DAB2IP, DLC-1, Integrin alpha4, and RUNX3 (Fig. 1). However, promoter hypermethylation of the 22 normal peripheral bloods was observed less frequently (Table 2).
###end p 14
###begin p 15
###xml 140 143 140 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 145 150 145 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 187 188 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 315 319 315 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 358 359 358 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 542 545 542 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 547 552 547 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 558 562 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 608 609 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 617 618 617 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 631 632 631 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 655 662 655 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 762 767 762 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DLC-1</italic>
###xml 769 775 769 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DAB2IP</italic>
###xml 777 787 777 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H-cadherin</italic>
###xml 789 804 789 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Integrin &#945;4</italic>
###xml 810 815 806 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 909 915 905 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 494 502 <span type="species:ncbi:9606">patients</span>
There was a statistically significant difference between normal peripheral bloods and AML with respect to the frequencies of methylation of ID4, SFRP1, and SHP1 (Pearson chi-square test; P<0.0001, P<0.0001, and P<0.0001, respectively) and between normal peripheral bloods and CML with respect to the frequencies of SHP1 methylation (Pearson chi-square test; P=0.007). Furthermore, there was a statistically significant difference between the DNA methylation frequencies of AML patients and CML patients. The frequencies of DNA methylation of ID4, SFRP1, and SHP1 were higher in AML compared to those in CML (P=0.001, P<0.0001, and P=0.001, respectively) (Table 2). In contrast, no statistical differences between AML and CML were detected in other genes such as DLC-1, DAB2IP, H-cadherin, Integrin alpha4, and RUNX3. Promoter methylation results at selected locus of eight genes with MSP method were shown in Fig. 1. These results suggest that there may be differential epigenetic modification between AML and CML.
###end p 15
###begin title 16
DISCUSSION
###end title 16
###begin p 17
###xml 187 190 187 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Differential epigenetic alteration is observed in AML and CML patients. The results of the present study demonstrate the substantially increased frequency of promoter hypermethylation in ID4, SFRP1, and SHP1 genes in AML compared to CML.
###end p 17
###begin p 18
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 574 582 574 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AML1-ETO</italic>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
Leukemia, a heterogeneous group of hematopoietic malignancies that occur worldwide, includes acute and chronic myeloid leukemia. Despite many important advances in understanding the different biological and cytogenetic aspects of acute and chronic leukemia, a number of questions remained unanswered. It is understood that some kinds of leukemia present specific cytogenetic alterations (21). Different types of leukemia usually have specific epigenetic modifications that cause the activation of oncogenes and, in particular, the formation of abnormal fusion genes such as AML1-ETO (22, 23), a fusion protein resulting from t(8,21) translocation that commonly occurs in AML. Another typical example is the fact that Bcr-Abl is a constitutively active, cytoplasmic tyrosine kinase that is generated by t(9;22) translocation in more than 95% of CML (24).
###end p 18
###begin p 19
###xml 222 225 222 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHIP1</italic>
The central role of epigenetic modification of these genes in leukemia development promoted them as reasonable targets for understanding the differential mechanism between acute and chronic leukemia. In the present study, ID4, SFRP1, and SHIP1 were hypermethylated in AML compared to CML. These results suggest that the epigenetic modification of these genes may play specific roles in the development of AML rather than CML and, thus, promoted them as ideal targets for drug development to treat AML. In the future, it is clearly imperative to understand the patho-physiological differential mechanisms of these genes in AML, and to finally explore novel therapeutic strategies.
###end p 19
###begin p 20
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 592 596 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 374 379 <span type="species:ncbi:9606">human</span>
In present study, methylation frequencies of SHP1 gene were the high detected in CML as well as AML. SHP1 is a member of the SHP family of proteins, cytoplasmic protein tyrosine phosphatase (PTP), and has been known as a candidate tumor suppressor gene in lymphoma, leukemia and other cancers (25). Also, the hypermethylation of SHP1 gene was frequently detected in several human cancers and the reduced expression of the SHP1 gene in various types of leukemias and lymphomas mainly occurred by promoter methylation (26-28). Therefore, these results indicate that aberrant DNA methylation of SHP1 gene may be related to the tumorigenicity of myeloid leukemia.
###end p 20
###begin p 21
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DAB2IP</italic>
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DLC-1</italic>
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 199 214 199 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Integrin &#945;4</italic>
###xml 420 422 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 424 426 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 428 430 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 432 434 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
The methylation frequencies of the DAB2IP, DLC-1, and RUNX3 genes were detected at different levels in acute and chronic leukemia patients; however, the difference was negligible. In some genes like Integrin alpha4 gene, the promoter methylation was not observed in most of the cases. However, hypermethylation of these genes was frequent event in esophageal squamous cell carcinomas, lung cancers, and gastric cancers (11, 12, 15, 16). Thus, DNA methylation of these genes may be not related to tumorigenicity of AML/CML in contrast with other cancers.
###end p 21
###begin p 22
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 197 200 197 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 202 207 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 213 217 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 533 537 533 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 614 617 614 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 619 624 619 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 630 634 630 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
In summary, we have identified that aberrant DNA methylation of SHP1 is a frequent event in AML and CML. Also, the frequencies of DNA methylation of several methylation-controlled genes, including ID4, SFRP1, and SHP1, were higher in AML patients compared to those in CML patients. Although these results should be confirmed, more comprehensive studies are necessary involving various known risk factors such as smoking and occupational carcinogens, and genetic susceptibilities. Our results suggest that aberrant DNA methylation of SHP1 may be related to the tumorigenicity of AML and CML and hypermethylation of ID4, SFRP1, and SHP1 genes may contribute to the pathogenesis mechanism of AML specifically.
###end p 22
###begin p 23
###xml 28 64 28 64 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Korea University College of Medicine</funding-source>
This study was supported by Korea University College of Medicine grant.
###end p 23
###begin article-title 24
###xml 27 32 <span type="species:ncbi:9606">human</span>
Genomic hypomethylation in human chronic lymphocytic leukemia
###end article-title 24
###begin article-title 25
DNA methylation in cancer: too much, but also too little
###end article-title 25
###begin article-title 26
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment
###end article-title 26
###begin article-title 27
Microsatellite instability and hMLH1 promoter hypermethylation in Richter's transformation of chronic lymphocytic leukemia
###end article-title 27
###begin article-title 28
Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation
###end article-title 28
###begin article-title 29
DNA methyltransferase inhibitors and the development of epigenetic cancer therapies
###end article-title 29
###begin article-title 30
###xml 40 45 40 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INK4B</sup>
###xml 53 58 53 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INK4A</sup>
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies
###end article-title 30
###begin article-title 31
Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies
###end article-title 31
###begin article-title 32
Hypermethylation of E-cadherin in leukemia
###end article-title 32
###begin article-title 33
Frequent hypermethylation of p16 and p15 genes in multiple myeloma
###end article-title 33
###begin article-title 34
###xml 33 38 <span type="species:ncbi:9606">human</span>
Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers
###end article-title 34
###begin article-title 35
Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells
###end article-title 35
###begin article-title 36
Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker
###end article-title 36
###begin article-title 37
Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma
###end article-title 37
###begin article-title 38
###xml 48 53 <span type="species:ncbi:9606">human</span>
Aberrant methylation of integrin alpha4 gene in human gastric cancer cells
###end article-title 38
###begin article-title 39
Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma
###end article-title 39
###begin article-title 40
###xml 69 74 <span type="species:ncbi:9606">human</span>
Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers
###end article-title 40
###begin article-title 41
Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma
###end article-title 41
###begin article-title 42
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
###end article-title 42
###begin article-title 43
###xml 65 70 <span type="species:ncbi:9606">human</span>
Establishment and characterization of chromosomal aberrations in human cholangiocarcinoma cell lines by cross- species color banding
###end article-title 43
###begin article-title 44
Transcription factor fusions in acute leukemia: variations on a theme
###end article-title 44
###begin article-title 45
c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression
###end article-title 45
###begin article-title 46
Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells
###end article-title 46
###begin article-title 47
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
###end article-title 47
###begin article-title 48
The function of the protein tyrosine phosphatase SHP-1 in cancer
###end article-title 48
###begin article-title 49
SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway
###end article-title 49
###begin article-title 50
SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway
###end article-title 50
###begin article-title 51
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
###end article-title 51
###begin p 52
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DAB2IP</italic>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DLC-1</italic>
###xml 41 51 41 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H-Cadherin</italic>
###xml 53 56 53 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ID4</italic>
###xml 58 73 58 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Integrin &#945;4</italic>
###xml 75 80 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 82 87 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 93 97 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHP1</italic>
PCR product images of the DAB2IP, DLC-1, H-Cadherin, ID4, Integrin alpha4, RUNX3, SFRP1, and SHP1 genes in normal peripheral bloods, acute myeloid leukemias, and chronic myeloid leukemias.
###end p 52
###begin p 53
N, normal peripheral blood; A, acute myeloid leukemia; C, chronic myeloid leukemias; U, amplified products used as primers for the unmethylated sequence in normal peripheral blood; M, amplified products used as primers for the methylated sequence.
###end p 53
###begin p 54
Sequences of primers and PCR conditions
###end p 54
###begin p 55
PCR, polymerase chain reaction; temp., temperature; UF, unmethylated forward-sequence; UR, unmethylated reverse-sequence; MF, methylated forward-sequence; MR, methylated reverse-sequence.
###end p 55
###begin p 56
Methylation frequencies in normal peripheral bloods, acute myeloid leukemias, and chromic myeloid leukemias
###end p 56
###begin p 57
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
*P<0.05.
###end p 57
###begin p 58
N, normal peripheral bloods; A, acute myeloid leukemia; C, chronic myeloid leukemia.
###end p 58

